KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Cash from Investing Activities (2016 - 2025)

Idexx Laboratories has reported Cash from Investing Activities over the past 17 years, most recently at -$28.1 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$28.1 million for Q4 2025, up 29.4% from a year ago — trailing twelve months through Dec 2025 was -$136.2 million (up 34.2% YoY), and the annual figure for FY2025 was -$136.2 million, up 34.2%.
  • Cash from Investing Activities for Q4 2025 was -$28.1 million at Idexx Laboratories, up from -$44.9 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for IDXX hit a ceiling of -$24.6 million in Q1 2021 and a floor of -$174.7 million in Q2 2021.
  • Median Cash from Investing Activities over the past 5 years was -$39.7 million (2023), compared with a mean of -$47.8 million.
  • Biggest five-year swings in Cash from Investing Activities: plummeted 611.28% in 2021 and later surged 72.31% in 2025.
  • Idexx Laboratories' Cash from Investing Activities stood at -$44.0 million in 2021, then decreased by 11.78% to -$49.2 million in 2022, then soared by 38.18% to -$30.4 million in 2023, then tumbled by 30.91% to -$39.8 million in 2024, then grew by 29.4% to -$28.1 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$28.1 million (Q4 2025), -$44.9 million (Q3 2025), and -$33.6 million (Q2 2025) per Business Quant data.